Anteris Technologies Global Corp (AVR)

$4.21 -0.06 (-1.41%)
Market Cap 156.87M
Revenue (ttm) 2.70M
Net Income (ttm) -76.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,825.56%
Debt to Equity Ratio 0.02
Volume 105,061
Avg Vol 276,420
Day's Range N/A - N/A
Shares Out 36.06M
Stochastic %K 6%
Beta N/A
Analysts Strong Sell
Price Target $16.50

Company Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bios...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 61 7 3152 3200
Address:
Toowong Tower, Level 3, Suite 302 9 Sherwood Road, Toowong, Australia
GuadalupeBono252
GuadalupeBono252 Nov. 4 at 4:37 PM
$AVR advances its position in tech development while market demand for automation grows as AITX adds a major U.S. healthcare system client, moving from pilot to paid deployments as hospitals adopt RIO 360 units to enhance safety and efficiency.
0 · Reply
PaulBEquity
PaulBEquity Nov. 3 at 4:00 PM
$AVR significantly undervalued.. TD, Barclays, Cantor, Lake Street all reputable names
0 · Reply
DillowWesgreaves
DillowWesgreaves Nov. 3 at 12:31 PM
$AVR Undervalued... Nice pipeline, went down significantly since announced start of pivotal trial phase, have seen some stocks go up 50-70% when announcing this, (humacyte, apellis, etc). Will be up and on from here
0 · Reply
StockScanners
StockScanners Nov. 1 at 6:30 PM
$AVR reached 4.75
0 · Reply
sk7777777
sk7777777 Oct. 30 at 9:09 PM
$AVR
0 · Reply
Goldenpoint9
Goldenpoint9 Oct. 30 at 11:04 AM
$AVR
0 · Reply
jagstox
jagstox Oct. 29 at 10:41 PM
$AVR Pure manipulation by Wal St "Institution" Ba4turds"...They stole some more shares from Retail!
0 · Reply
OliverBroderick
OliverBroderick Oct. 29 at 3:40 PM
$AVR still undervalued, pivotal trial phase is a big deal, seen 50-70% moves on pivotal trial phase starting for appelis, humacyte, iRhythm and their TAM wasn't $10B. Liking vertical integration with factory development, still think should be far north of $6, shouldn't be down 15%+ this week on all positive news
0 · Reply
jdlman
jdlman Oct. 28 at 10:29 PM
$AVR any news here?
0 · Reply
RAIK7
RAIK7 Oct. 28 at 10:16 PM
$AVR https://www.stocktitan.net/news/AVR/anteris-dur-avr-thv-demonstrates-favorable-hemodynamics-in-small-5l6a14c3fyid.html
0 · Reply
Latest News on AVR
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Oct 27, 2025, 5:43 PM EDT - 9 days ago

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Oct 27, 2025, 8:43 AM EDT - 9 days ago

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Sep 19, 2025, 2:30 AM EDT - 6 weeks ago

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Sep 11, 2025, 8:50 AM EDT - 7 weeks ago

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Announces Results for the Second Quarter of 2025

Aug 11, 2025, 4:52 PM EDT - 3 months ago

Anteris Announces Results for the Second Quarter of 2025

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Jun 9, 2025, 10:52 PM EDT - 5 months ago

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Mar 31, 2025, 7:15 AM EDT - 7 months ago

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Mar 21, 2025, 7:30 AM EDT - 8 months ago

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Anteris Reports 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:33 PM EDT - 8 months ago

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Dec 16, 2024, 7:49 PM EST - 11 months ago

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Dec 12, 2024, 10:34 PM EST - 11 months ago

Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Dec 9, 2024, 7:43 AM EST - 11 months ago

Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering

Cardiac device maker Anteris Technologies files for $75M IPO

Nov 22, 2024, 1:54 PM EST - 1 year ago

Cardiac device maker Anteris Technologies files for $75M IPO

Australian medical device company Anteris Technologies Global files for a $75 million US IPO

Nov 22, 2024, 12:09 PM EST - 1 year ago

Australian medical device company Anteris Technologies Global files for a $75 million US IPO

Anteris Technologies Global IPO Registration Document (S-1)

Nov 22, 2024, 11:09 AM EST - 1 year ago

Anteris Technologies Global IPO Registration Document (S-1)

GuadalupeBono252
GuadalupeBono252 Nov. 4 at 4:37 PM
$AVR advances its position in tech development while market demand for automation grows as AITX adds a major U.S. healthcare system client, moving from pilot to paid deployments as hospitals adopt RIO 360 units to enhance safety and efficiency.
0 · Reply
PaulBEquity
PaulBEquity Nov. 3 at 4:00 PM
$AVR significantly undervalued.. TD, Barclays, Cantor, Lake Street all reputable names
0 · Reply
DillowWesgreaves
DillowWesgreaves Nov. 3 at 12:31 PM
$AVR Undervalued... Nice pipeline, went down significantly since announced start of pivotal trial phase, have seen some stocks go up 50-70% when announcing this, (humacyte, apellis, etc). Will be up and on from here
0 · Reply
StockScanners
StockScanners Nov. 1 at 6:30 PM
$AVR reached 4.75
0 · Reply
sk7777777
sk7777777 Oct. 30 at 9:09 PM
$AVR
0 · Reply
Goldenpoint9
Goldenpoint9 Oct. 30 at 11:04 AM
$AVR
0 · Reply
jagstox
jagstox Oct. 29 at 10:41 PM
$AVR Pure manipulation by Wal St "Institution" Ba4turds"...They stole some more shares from Retail!
0 · Reply
OliverBroderick
OliverBroderick Oct. 29 at 3:40 PM
$AVR still undervalued, pivotal trial phase is a big deal, seen 50-70% moves on pivotal trial phase starting for appelis, humacyte, iRhythm and their TAM wasn't $10B. Liking vertical integration with factory development, still think should be far north of $6, shouldn't be down 15%+ this week on all positive news
0 · Reply
jdlman
jdlman Oct. 28 at 10:29 PM
$AVR any news here?
0 · Reply
RAIK7
RAIK7 Oct. 28 at 10:16 PM
$AVR https://www.stocktitan.net/news/AVR/anteris-dur-avr-thv-demonstrates-favorable-hemodynamics-in-small-5l6a14c3fyid.html
0 · Reply
Market_Crasher
Market_Crasher Oct. 28 at 2:54 PM
$AVR This dead ass thing finally moved a little.
0 · Reply
prismmarketview
prismmarketview Oct. 28 at 2:33 PM
(NASDAQ: $AVR) Anteris Technologies has treated the first patients in its PARADIGM pivotal trial for the DurAVR® heart valve, advancing toward regulatory approval and targeting the multi-billion-dollar TAVR market. https://prismmarketview.com/anteris-technologies-treats-first-patients-in-global-pivotal-trial-for-duravr-heart-valve/
0 · Reply
PaulBEquity
PaulBEquity Oct. 28 at 2:10 PM
$AVR https://www.australianmanufacturing.com.au/38-5m-investment-to-expand-anteris-manufacturing-capacity-global-clinical-program/ There's literally umpteen reasons for them to be up, is vertical integration bad now??
0 · Reply
sk7777777
sk7777777 Oct. 28 at 2:01 PM
$AVR Just read and digest this and then sit back and relax. An easy double from here and worth a lot more. https://financialpost.com/globe-newswire/anteris-technologies-announces-first-patients-treated-in-duravr-thv-global-pivotal-trial-the-paradigm-trial
1 · Reply
sk7777777
sk7777777 Oct. 28 at 1:40 PM
$AVR Not worried here. A little patience.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 28 at 1:37 PM
$IPDN -13%[-1%] $SMX -10%[-22%] $METC -8%[-16%] $CDZI 7%[6%] $AVR -7%[-15%] most notable movement within the first minutes of trading.
0 · Reply
OliverBroderick
OliverBroderick Oct. 28 at 1:36 PM
$AVR I am still baffled $AVR is down 18% on the week when they just launched their pivotal trial makes 0 sense.
0 · Reply
jagstox
jagstox Oct. 28 at 12:35 PM
$AVR This will be taken out in a BO at 60+ in 6 months! Why is this not at 20+ on this Amazing News? Mkt is a Mechanism of Transfer of Wealth from the Impatient to the Patient: Warren Buffet
0 · Reply
ValueInflection
ValueInflection Oct. 28 at 12:34 PM
$AVR this hit $8.50 after hours last night. now is down pre-market. someone explain this to me???
0 · Reply
Mr_patience_MAN
Mr_patience_MAN Oct. 28 at 10:35 AM
$AVR Help😰😰 I'm in at 4.64😓
0 · Reply
PaulLaurent
PaulLaurent Oct. 28 at 6:03 AM
🚀📈 Top Gainers 📈🚀AH ​ $SDA $XHLD $SCWO $AVR $ETHZ
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Oct. 28 at 5:20 AM
no guessing with $AVR - just wait for H% to be low. Examples from my prev plays.
0 · Reply